Somaliq Pen 60 IU SunSci Pharmaceutical
*the price is for the package
Important! If the amount of your check exceeds 300 euros, we will deliver the goods to you free of charge! From 200 to 300 euros - shipping costs 25 euros. When ordering less than 200 euros - delivery is 45 euros!
Packaging video review Somaliq Pen 60 IU SunSci Pharmaceutical
Product form: Pen-syringe.
Somatropin is identical in its composition and effects to human pituitary GH (a single-stranded polypeptide consisting of 191 amino acid residues, the amino acid sequence of the drug is identical to human growth hormone).
Genetically engineered somatotropic hormone, which acts on the epiphysis plates of tubular bones, stimulates the growth of skeletal bones.
Replacement therapy in childhood in patients with endogenous STH deficiency (pituitary nanism), including CRF, Prader-Willi syndrome; Shereshevsky-Turner syndrome; replacement therapy for severe STH deficiency in adults. In the literature, there are reports of the use of somatotropin for the symptomatic treatment of the following diseases (indications are not approved): kwashiorkor, osteoporosis, cachexia, or significant weight loss in AIDS patients.
Hypersensitivity, brain tumors, malignant tumors of any localization (possible acceleration of their growth, possible treatment after effective antitumor therapy), epiphysis closure, emergency conditions (including conditions after heart surgery, abdominal cavity, acute respiratory failure) .With caution. Diabetes mellitus (possible decrease in insulin sensitivity), intracranial hypertension, hypothyroidism (unpredictable decrease in the effect of GH administration), pregnancy, lactation.
In / M, with low growth due to insufficient endogenous secretion of growth hormone-12 IU / sq. m / week or 0.6 IU / kg / week; with ineffectiveness, the dose is increased to 20 IU / sq. m / week or to 0.8 IU / kg / week. The weekly dose should be divided into 3-6 injections (4 IU / sq. m or 0.2 IU / kg). Injections should be given in the evenings. With insufficient growth in patients with gonadal dysgenesis (Turner syndrome) -18 IU / sq. m / week or 0.6-0.7 IU / kg / week. In the second year of treatment, the dose can be increased to 24 IU / sq. m per week or 0.8-1 IU / kg per week. The weekly dose of the drug should be divided into 7 single injections of 2.6 IU / sq. m or 0.09-0.1 IU / kg. In some cases, when treating patients with Turner syndrome, it may be necessary to increase the dose as early as the first year of treatment.
Treatment is discontinued when the patient reaches growth sufficient for an adult, or when the epiphysis of the tubular Bones is closed.
Headache, excessive fatigue or weakness, epiphyseolysis of the femoral head (lameness, hip and knee pain), peripheral edema in the first weeks of treatment, arthralgia, myalgia, increased intracranial pressure (severe and frequent headaches, nausea, vomiting, visual disturbances, edema of the optic disc (usually observed during the first 8 weeks of treatment, most often found in patients with Shereshevsky-Turner syndrome), pancreatitis (abdominal pain, nausea, vomiting), otitis media and hearing impairment (in patients with the syndrome Shereshevsky-Turner ), gynecomastia, muscle pain, joint pain, tunnel syndrome, fluid retention, peripheral edema, leukemoid reactions, acceleration of the growth of a pre-existing nevus (possible malignant neoplasm). Progression of scoliosis (in patients with excessively rapid growth).
Allergic reactions: skin rash, itching. Local reactions in the injection area: soreness, numbness, hyperemia, edema, lipoatrophy, pruritus. A small percentage of patients have the formation of antibodies to GH with a decrease in its effectiveness. Increased blood concentrations of inorganic phosphate, parathyroid hormone, and alkaline phosphatase activity.
Symptoms: single overdose-hypoglycemia followed by hyperglycemia, rarely-glucosuria. Long – term use of excessive doses-acromegaly and / or gigantism, hypothyroidism, decreased serum cortisol levels.
Treatment: drug withdrawal, symptomatic therapy.
It is possible to form antibodies to the drug and Escherichia coli proteins. To avoid atrophy of subcutaneous fat at the injection site, it is necessary to change the injection site every time. The possible occurrence of hypothyroidism during treatment should be corrected by TSH administration to achieve the effect of increasing growth (control of thyroid function). The drug is ineffective if low growth is due to the inability of the body to synthesize growth factors or the lack of receptors for liver growth factors – somatomedin, formed under the influence of somatotropin.
Patients with diabetes mellitus should be under close medical supervision during treatment (monitoring the level of glucose in the blood, urine); correction of hypoglycemic therapy is necessary. Before and during treatment, in the presence of severe or recurrent headaches, visual disturbances, nausea, vomiting, it is recommended to examine the fundus (fundoscopy) in order to detect edema of the optic nerve and associated intracranial hypertension. In this case, it is necessary to stop treatment. In chronic renal failure, the drug is prescribed with a decrease in renal function by more than 50%. Against the background of treatment, conservative treatment of CRF should be carried out.
The drug should be discontinued after kidney transplantation. Patients with chronic renal failure may develop renal osteodystrophy, including those accompanied by necrosis of the femoral head (more often observed in patients with concomitant endocrine pathology or excessively rapid growth). Epiphyseolysis of the tubular bone heads is more common in patients with endocrine disorders, including growth hormone deficiency. Detection of lameness during therapy requires careful monitoring. Some dosage forms contain benzyl alcohol, which is toxic to newborns, as a preservative.